Ronifibrate
Chemical compound
- C10AB07 (WHO)
- 3-{[2-(4-chlorophenoxy)-2-methylpropanoyl]oxy}propyl nicotinate
- 42597-57-9
N
- 68671
- 61925
Y
- W86I18X716
- ChEMBL153983 Y
- DTXSID80195362
- Interactive image
- O=C(OCCCOC(=O)C(Oc1ccc(Cl)cc1)(C)C)c2cccnc2
InChI
- InChI=1S/C19H20ClNO5/c1-19(2,26-16-8-6-15(20)7-9-16)18(23)25-12-4-11-24-17(22)14-5-3-10-21-13-14/h3,5-10,13H,4,11-12H2,1-2H3Y
- Key:AYJVGKWCGIYEAK-UHFFFAOYSA-NY
N
Y (what is this?) (verify)Ronifibrate is a fibrate, a hypolipidemic agent. It is a combined ester of clofibric acid and niacin (nicotinic acid) with 1,3-propanediol. In the body, the ester is split to 1,3-propanediol and both acids which work in the same way, lowering lipids in blood.
References
- v
- t
- e
| Cholesterol absorption inhibitors, NPC1L1 | |
|---|---|
| Bile acid sequestrants/resins (LDL) |
| Statins (HMG-CoA reductase, LDL) | |
|---|---|
| Niacin and derivatives (HDL and LDL) | |
| MTTP inhibitors (VLDL) | |
| ATP citrate lyase inhibitors (LDL) | |
| Thyromimetics (VLDL) |
| PPAR agonists (LDL) |
| ||||
|---|---|---|---|---|---|
| CETP inhibitors (HDL) | |||||
| PCSK9 inhibitors (LDL) | |||||
| ANGPTL3 inhibitors (LDL/HDL) |
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
 | This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
